Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
August 16 2021 - 8:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of August 2021
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
16
Tiomkin St.
Tel
Aviv 6578317, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form
20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation
S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation
S-T Rule 101(b)(7): ☐
Attached
hereto and incorporated herein by reference is a press release, dated August 16, 2021, and entitled “MHRA Agrees with Galmed’s
Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study”.
The
first paragraph and “Forward-Looking Statements” of the press release attached to this Form 6-K is incorporated by reference
into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration
Statement on Form F-3 (Registration No. 333-254766).
EXHIBIT INDEX
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Galmed
Pharmaceuticals Ltd.
|
|
|
|
Date:
August 16, 2021
|
By:
|
/s/
Allen Baharaff
|
|
|
Allen
Baharaff
|
|
|
President
and Chief Executive Officer
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Sep 2023 to Sep 2024